+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 11 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the clinical effects of tislelizumab combined with chemotherapy in US racial and ethnic minority patients who have HER2-negative, PD-L1-positive, locally advanced unresectable or metastatic gastric or gastroesophageal adenocarcinoma GACGEA or esophageal squamous cell carcinoma ESCC. This Phase 2 study aims to assess the pharmacokinetics, activity, and safety of this combination treatment over a period of up to approximately 6 years. Participants will receive tislelizumab given by intravenous infusion at either 200 mg every 3 weeks or 150 mg every 2 weeks, depending on the chemotherapy regimen. The chemotherapy options include FOLFOX oxaliplatin, leucovorin, and 5-fluorouracil, CAPOX oxaliplatin plus oral capecitabine, or cisplatin plus 5-fluorouracil, administered in cycles every 2 or 3 weeks. The study is open-label and non-randomized with two study arms based on the type of cancer. During the study, participants will be monitored for adverse events and serious adverse events for about 12 months. Researchers will also assess tumor response, measure serum levels of tislelizumab, and check for antidrug antibodies. Eligibility assessments include tumor PD-L1 status and organ function tests. The study includes regular visits for treatment administration and safety evaluations, with participants followed for up to six years to gather long-term data.

Age: 18Years +All GendersPhase 2
9 locations
R

Actively Recruiting

Researchers are evaluating the effects of biweekly XEMBIFY combined with Standard Medical Treatment SMT over one year in adults with hypogammaglobulinemia HGG who have B-cell Chronic Lymphocytic Leukemia CLL, Multiple Myeloma MM, or Non-Hodgkin Lymphoma NHL. The study aims to determine if this combination reduces the yearly rate of major bacterial infections compared to a placebo plus SMT. This Phase 3 trial is randomized, double-blinded, and placebo-controlled to ensure reliable results. Participants will receive either XEMBIFY or a placebo via subcutaneous infusion. The treatment starts with a loading dose of 150 mgkgday given daily for five days in the first week, followed by biweekly infusions of 300 mgkg from Week 3 through Week 51. Along with the study drug or placebo, all participants will continue to receive their usual standard medical treatments and supportive care needed during the trial. During the study, participants will be regularly monitored to assess the rate and timing of major bacterial infections and other infection-related outcomes. Researchers will track hospitalizations, antibiotic use, and overall infection rates up to Week 51. Safety and pharmacokinetics of the treatment will also be evaluated throughout. The total participation period lasts about one year, during which participants will have scheduled visits for treatment administration and assessments.

Age: 18Years +All GendersPhase 3
62 locations
C

Actively Recruiting

Researchers are evaluating the effectiveness of Pumitamig compared to Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer NSCLC who have a PD-L1 expression of 50% or higher. This Phase 3, randomized, double-blind study focuses on participants with locally advanced or metastatic NSCLC, aiming to understand which treatment better controls the disease and improves survival outcomes. Participants are randomly assigned to receive either Pumitamig or Pembrolizumab at specified doses on specified days. The study compares these two drugs as first-line treatments for their impact on disease progression and overall survival. The treatment period may last up to approximately five years to assess long-term outcomes. During the study, participants will undergo regular assessments including imaging and symptom questionnaires to evaluate progression-free survival and overall survival. Researchers will also monitor objective response, duration of response, disease control rate, and symptom changes using established criteria. Safety and effectiveness will be closely followed throughout the study, which lasts up to about five years from enrollment.

Age: 18Years +All GendersPhase 3
283 locations
E

Actively Recruiting

Researchers are investigating the safety, tolerability, and clinical activity of belantamab, alone and in combination with other drugs, in participants with multiple myeloma. The study is divided into three parts Part 1 evaluates escalating doses of belantamab in participants with refractory multiple myeloma who have had at least three prior therapies Part 2 assesses different doses of belantamab combined with belantamab mafodotin in a similar participant group Part 3 studies belantamab combined with a pomalidomide-dexamethasone standard treatment in participants who have received at least one prior therapy including lenalidomide. This phase 12 open-label trial aims to explore these treatments in participants with advanced disease. Participants receive belantamab monotherapy, belantamab with belantamab mafodotin, or belantamab with pomalidomide and dexamethasone, depending on study part. In Parts 1 and 2, treatment continues until disease progression, after which participants may opt for belantamab mafodotin alone. The study uses a sequential design with randomized allocation. Each treatment is administered as specified, and dosing adjusts according to safety and tolerability evaluations. During the study, participants undergo regular monitoring for adverse events, dose-limiting toxicities, and changes in laboratory and vital signs up to 52 months. Specific assessments include ocular event severity, response rates, and pharmacokinetic measurements. The study also tracks immunogenicity by measuring anti-drug antibodies. Researchers evaluate clinical activity through overall response rates and disease progression metrics while ensuring participant safety through ongoing evaluations and compliance monitoring.

Age: 18Years +All GendersPhase 1Phase 2
44 locations
O

Actively Recruiting

Researchers are evaluating the safety and effectiveness of BGB-43395 combined with letrozole compared to a choice of approved cyclin-dependent kinase 46 inhibitors abemaciclib, palbociclib, or ribociclib combined with letrozole in adults with advanced or metastatic hormone receptor positive HR and human epidermal growth factor receptor 2 negative HER2- breast cancer. The study focuses on patients who have not previously received systemic treatment for advanced or metastatic disease. This phase 3 trial aims to provide insight into treatment options for this patient group. Participants are randomly assigned to one of two groups one receiving BGB-43395 plus letrozole, and the other receiving an investigators choice of CDK46 inhibitor abemaciclib, palbociclib, or ribociclib plus letrozole. All medications are taken orally. The study compares these treatment combinations over a period lasting up to approximately 4 years for primary outcomes, with longer follow-up for secondary outcomes. During the trial, participants will be regularly monitored for disease progression, response to treatment, overall survival, and safety through various assessments. These include evaluations of progression-free survival by independent review, overall response rate, duration of response, clinical benefit rate, and adverse events. Quality of life measures and other clinical outcomes are also tracked. Participant involvement may last up to 11 years to capture long-term effects and safety.

Age: 18Years +All GendersPhase 3
241 locations
E

Actively Recruiting

Researchers are evaluating how effective trastuzumab deruxtecan T-DXd is for patients in the US with HER2-positive IHC 3 solid tumors that are locally advanced, cannot be removed by surgery, or have spread to other parts of the body. These patients have already received prior systemic treatments for advanced disease and currently have no satisfactory treatment options. The study focuses on a real-world setting to better understand treatment outcomes outside of controlled clinical trials. This is a multicenter, hybrid observational study involving about 100 patients who start T-DXd treatment as part of their routine care following FDA guidelines. Patients with certain cancers like breast, colorectal, non-small cell lung, gastricgastroesophageal junction cancers, or blood cancers are not included. The study takes place at approximately 30 sites including community practices, hospitals, and academic centers to reflect typical care environments. Participants will be observed from the start of their T-DXd treatment with data collected on their response to therapy, how long the response lasts, time until treatment stops, and time until the next treatment begins. These outcomes will be tracked for up to 2.5 years after enrollment. No additional interventions are given beyond usual care, and patients will provide informed consent before joining the study.

Age: 18Years - 130YearsAll Genders
18 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of Olvimulogene nanivacirepvec Olvi-Vec, an intravenously delivered oncolytic vaccinia virus, in combination with platinum-based chemotherapy and a physicians choice of immune checkpoint inhibitor ICI compared to docetaxel in patients with advanced or metastatic non-small-cell lung cancer NSCLC. This Phase 2, open-label, randomized study focuses on patients who have shown first disease progression while on front-line or maintenance ICI therapy following platinum-doublet chemotherapy. The study aims to test if Olvi-Vec can activate the immune system and make tumors more responsive to chemotherapy in NSCLC patients without certain targetable genetic alterations. Participants will be assigned to one of several groups. Initial cohorts receive varying doses of Olvi-Vec over 3 or 4 consecutive days, followed 2 to 3 weeks later by platinum-doublet chemotherapy combined with a physician-chosen ICI. The experimental arm will use the Olvi-Vec dose and schedule selected from these cohorts, followed by platinum-based chemotherapy plus ICI. The comparator arm receives docetaxel starting in week 0 and continuing until disease progression is confirmed. Patients in the comparator arm with disease progression may cross over to receive the experimental treatment if eligible. During the study, participants will undergo regular assessments including imaging scans to measure tumor response and progression-free survival up to 12 months after randomization. Researchers will monitor treatment safety and side effects for up to 36 months. Additional measures include overall survival, disease control rate, and treatment response duration. Scheduled visits will involve laboratory tests, imaging, and clinical evaluations to track health and disease status throughout the trial.

Age: 18Years +All GendersPhase 2
15 locations
M

Actively Recruiting

Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.

Age: 18Years +All Genders
2393 locations
M

Actively Recruiting

Researchers are collecting clinical data and biological samples from adults diagnosed with stage I, stage II, or operable stage III cancers in certain solid tumor types. This observational study aims to help develop tests that improve cancer detection and assess the risk of cancer returning. Participants continue to receive standard care from their own doctors throughout the study. Participants will provide blood and tumor tissue samples during their routine care. The study includes several tumor groups such as bladder cancer, esophageal cancer, gastric and gastroesophageal junction cancer, melanoma, non-small cell lung cancer, pancreatic cancer, and a mix of other solid tumors. Enrollment occurs either before or within three months after surgery, and no prior systemic therapy for the current cancer is allowed before joining. During the approximately five and a half years of involvement, participants will be observed with collection of blood and tissue samples as part of a biospecimen registry. Researchers will use this information to study molecular residual disease in solid tumors. All clinical data and samples will be gathered under routine care settings, with no additional treatment provided by the study team.

Age: 18Years +All Genders
47 locations
S

Actively Recruiting

Researchers are evaluating the safety and effectiveness of SelfWrap, a bioabsorbable perivascular wrap, in patients with chronic kidney disease CKD who are referred for creation of a new arteriovenous fistula AVF. This multi-center, prospective, randomized, double-arm, single-blind clinical trial involves about 600 participants across up to 30 sites. The purpose is to compare SelfWrap-assisted AVF creation with the standard surgical procedure without any additional intervention over a 36-month follow-up period. Participants are randomly assigned to one of two groups one receiving the SelfWrap device during AVF creation surgery, and the other undergoing the usual AVF surgery without intervention as a control group. The SelfWrap device offers mechanical support intended to improve the maturation and patency of the fistula. The trial follows participants for 36 months after surgery to monitor outcomes. During the study, participants will undergo assessments to measure unassisted maturation of the AVF at up to 6 months and monitor freedom from access-related adverse events through 30 days. Researchers will evaluate safety and effectiveness through these primary outcome measures. Participants are expected to comply with study requirements and attend follow-up visits throughout the 36-month period to allow comprehensive evaluation of the devices impact and any complications.

Age: 18Years +All GendersPhase Not Applicable
28 locations

1-10 of 11

1